Stockreport

Nuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026 [Yahoo! Finance]

Nuvation Bio Inc. Class A  (NUVB) 
PDF median Duration of Response (DOR) now increased to 50 months as of August 2025 data cutoff Presentations will also highlight new data on the efficacy and safety of tal [Read more]